Form 4: Opus Genetics Director, Susan Benton, Receives Stock Grant and Options

Director Susan Benton acquired 79,504 shares of common stock and options to purchase 79,592 shares of common stock from Opus Genetics on April 30, 2025.

Summary

• On April 30, 2025, Susan Benton, a director of Opus Genetics, Inc., acquired 79,504 shares of common stock and options to purchase 79,592 shares of common stock.
• The common stock was acquired through a grant of restricted stock units.
• These restricted stock units vest upon the earlier of the one-year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, contingent upon Ms. Benton's continued service.
• The stock options have an exercise price of $0.95 and also vest upon the earlier of the one-year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, contingent upon Ms. Benton's continued service, and expire on April 29, 2035.
• Following these transactions, Ms. Benton directly owns 219,527 shares of Opus Genetics common stock and options to purchase 79,592 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and restricted stock units to a director is a common practice and generally viewed as a positive sign, aligning the director's interests with those of the shareholders. There are no negative aspects mentioned in the document.

Positives

• The grant of restricted stock units and options to a director aligns her interests with those of the shareholders.
• The vesting schedule, tied to continued service, incentivizes the director to remain with the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the stock and options is tied to the director's continued service.

Industry Context

This type of equity grant is common in the biotechnology industry to attract and retain qualified board members and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Equity compensation for board members in biotech companies typically includes a mix of stock options and restricted stock units.
• The vesting schedules are generally tied to continued service, often over a period of one to four years.
• The size of the grant is usually determined by the company's size, stage of development, and the director's role and responsibilities.
• Comparable companies such as Iveric Bio (acquired by Astellas), and ProQR Therapeutics provide similar equity-based compensation to their directors.

Stakeholder Impact

• The grant of equity to a director can positively impact shareholders by aligning management's interests with theirs.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Opus Genetics, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, IRD